IMA
NASDAQ · Pharmaceuticals
Imagenebio Inc
$5.69
+0.00 (+0.00%)
Financial Highlights (FY 2025)
Revenue
47.00M
Net Income
6.79M
Gross Margin
31.5%
Profit Margin
14.5%
Rev Growth
-8.8%
D/E Ratio
0.50
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 31.5% | 31.5% | 31.5% |
| Operating Margin | 13.7% | 13.4% | 16.1% |
| Profit Margin | 14.5% | 10.3% | 13.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.00M | 44.29M | 39.41M |
| Gross Profit | 14.82M | 13.97M | 12.43M |
| Operating Income | 6.44M | 5.94M | 6.35M |
| Net Income | 6.79M | 4.55M | 5.11M |
| Gross Margin | 31.5% | 31.5% | 31.5% |
| Operating Margin | 13.7% | 13.4% | 16.1% |
| Profit Margin | 14.5% | 10.3% | 13.0% |
| Rev Growth | -8.8% | -0.9% | +2.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 20.07M | 19.74M | 17.02M |
| Total Equity | 40.17M | 39.52M | 44.51M |
| D/E Ratio | 0.50 | 0.50 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 10.10M | 9.89M | 9.22M |
| Free Cash Flow | 2.61M | 3.33M | 3.29M |